<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04991376</url>
  </required_header>
  <id_info>
    <org_study_id>IK-01-miRNA</org_study_id>
    <secondary_id>01 - RVO - FNOs/2019</secondary_id>
    <nct_id>NCT04991376</nct_id>
  </id_info>
  <brief_title>Specific miRNAs in Sepsis and Nephrotoxic Antibiotic Treatment</brief_title>
  <official_title>Differentiation of Acute Kidney Injury in Sepsis and Due to Nephrotoxic Antibiotic Treatment With Vancomycin and Gentamicin Based on Measurements of Specific miRNAs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Ostrava</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Palacky University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Olomouc</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Ostrava</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Technical University of Ostrava</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Ostrava</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Critically ill patients are prone to develop acute kidney injury due to sepsis itself and by&#xD;
      administration of potentially nephrotoxic antibiotic treatment (vancomycin or gentamicin).&#xD;
      Blood-specific miRNA levels associated with renal tubular damage change in patients treated&#xD;
      with vancomycin or gentamicin compared to septic patients treated with other antimicrobials.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sepsis is generally defined as a life-threatening and dysregulated reaction to infection&#xD;
      (bacterial, fungal, or viral) leading to systemic inflammation and organ dysfunction&#xD;
      including acute kidney injury [1]. Acute kidney injury in critically ill patients is a common&#xD;
      and usually serious condition associated with increased patient morbidity and mortality.&#xD;
      Critically ill patients are prone to develop acute kidney injury due to sepsis itself and by&#xD;
      administration of potentially nephrotoxic antibiotic treatment (vancomycin or&#xD;
      aminoglycoside-gentamicin). To prevent nephrotoxicity and avoid subtherapeutic dosing, drug&#xD;
      serum concentrations are usually monitored, with adjustment of dose or dosing interval&#xD;
      according to the pharmacokinetic model. However, renal tubular injury can occur even if the&#xD;
      treatment is optimally set. In the quest for new preventive or therapeutic targets&#xD;
      (biomarkers) in septic/nephrotoxic acute renal damage, a current research focus in microRNAs.&#xD;
      Based on data from previously published experimental and human studies we identified specific&#xD;
      miRNAs associated with biochemical pathways involved in inflammation, organ ischemia, and&#xD;
      nephrotoxicity with their exact determination and time-changing detection during the seven&#xD;
      days in studied patients. Blood-specific miRNA levels associated with renal tubular damage&#xD;
      change in patients treated with vancomycin or gentamicin compared to septic patients treated&#xD;
      with other antimicrobials.&#xD;
&#xD;
      Sampling method:&#xD;
&#xD;
      Whole blood samples were taken on the first, fourth, and seventh days of antibiotic&#xD;
      treatment. The first 24 samples (8 patients) were extracted in duplicate for screening of the&#xD;
      selected miRNAs. Blood samples were collected into 2.5 mL tubes (Vacutainer® PAXgene,&#xD;
      PreAnalytiX® GmbH, A Qiagen/BD Company, Switzerland). Concomitant-ly, the blood samples for&#xD;
      NGAL determination were collected into 2.6 or 2 mL neutral tubes (S-Monovette® K3 EDTA, 2.6&#xD;
      mL, red, Sartstedt AG &amp; Co. KG, Germany; or Vacuette® K3 EDTA 2 mL, violet, Greiner Bio-One&#xD;
      GmbH, Germany). The blood samples for biochemical (renal and inflammatory) parameters (serum&#xD;
      creatinine, interleukin-6, procalcitonin, C-reactive protein) were collected concomitantly&#xD;
      with other dai-ly routine biochemical parameters (S-Monovette® serum-gel, 4.9 mL, brown,&#xD;
      Sartstedt AG &amp; Co. KG, Germany in University Hospital Ostrava; or Vacuette® serum-gel, 5.0&#xD;
      mL, red, Greiner Bio-One GmbH, Germany in University Hospital Olomouc). The serum antibiotic&#xD;
      concentrations (vancomycin and gentamicin) were monitored according to standard care in both&#xD;
      cooperating hospitals without needing more blood samples for study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 2, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Actual">June 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>miRNAs expression over 7 days of treatment</measure>
    <time_frame>7 days</time_frame>
    <description>Determine and investigate specific circulating miRNAs linked to sepsis itself, septic, ischemic, or nephrotoxic acute kidney injury in patients suffered from sepsis. Tracking changes in miRNAs expression over 7 days of treatment with nephrotoxic (vancomycin or gentamicin) as compared with other, non-nephrotoxic antibiotic treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Association between circulating miRNA expression and serum neutrophil gelatinase-associated lipocalin (NGAL) and other renal or inflammatory markers</measure>
    <time_frame>7 days</time_frame>
    <description>Association between circulating miRNA expression and serum neutrophil gelatinase-associated lipocalin (NGAL) and other renal or inflammatory markers to assess the potential of these small RNAs as pathophysiological biomarkers of nephrotoxic acute kidney injury or preventive, or therapeutic targets in sepsis and/or acute kidney injury.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">53</enrollment>
  <condition>Sepsis</condition>
  <condition>Septic Shock</condition>
  <condition>Acute Kidney Injury</condition>
  <arm_group>
    <arm_group_label>Vancomycin</arm_group_label>
    <description>Critically ill patients who suffered from sepsis, treated with vancomycin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gentamicin</arm_group_label>
    <description>Critically ill patients who suffered from sepsis, treated with gentamicin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Other antibiotic groups</arm_group_label>
    <description>Critically ill patients who suffered from sepsis, treated by other antibiotic groups except for vancomycin or aminoglycoside (gentamicin).</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood-specific miRNA levels</intervention_name>
    <description>Blood-specific miRNA levels associated with renal tubular damage change in patients treated with vancomycin or gentamicin compared to septic patients treated with other antimicrobials.</description>
    <arm_group_label>Gentamicin</arm_group_label>
    <arm_group_label>Other antibiotic groups</arm_group_label>
    <arm_group_label>Vancomycin</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Critically ill patients suffering from sepsis and treated with vancomycin, gentamicin, or&#xD;
        other antibiotic groups.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Critically ill adult septic patients with or without acute kidney injury treated by&#xD;
        antimicrobial therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Patients in the chronic dialysis program, with stage 4 and 5 chronic kidney disease, or&#xD;
        concomitantly treated with another potentially severe nephrotoxic medication (cisplatin,&#xD;
        colistin) or combination vancomycin/gentamicin.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Naděžda Petejová, Assoc.Prof.,MD,PhD,MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Ostrava</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Ostrava</name>
      <address>
        <city>Ostrava</city>
        <state>Moravian-Silesian Region</state>
        <zip>70852</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <reference>
    <citation>Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent JL, Angus DC. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016 Feb 23;315(8):801-10. doi: 10.1001/jama.2016.0287.</citation>
    <PMID>26903338</PMID>
  </reference>
  <reference>
    <citation>Eckardt KU, Kasiske BL. Kidney disease: improving global outcomes. Nat Rev Nephrol. 2009 Nov;5(11):650-7. doi: 10.1038/nrneph.2009.153. Epub 2009 Sep 29. Review.</citation>
    <PMID>19786993</PMID>
  </reference>
  <reference>
    <citation>Petejova N, Martinek A, Zadrazil J, Kanova M, Klementa V, Sigutova R, Kacirova I, Hrabovsky V, Svagera Z, Stejskal D. Acute Kidney Injury in Septic Patients Treated by Selected Nephrotoxic Antibiotic Agents-Pathophysiology and Biomarkers-A Review. Int J Mol Sci. 2020 Sep 26;21(19). pii: E7115. doi: 10.3390/ijms21197115. Review.</citation>
    <PMID>32993185</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 27, 2021</study_first_submitted>
  <study_first_submitted_qc>July 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2021</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sepsis</keyword>
  <keyword>septic shock</keyword>
  <keyword>acute kidney injury</keyword>
  <keyword>microRNA</keyword>
  <keyword>nephrotoxicity</keyword>
  <keyword>vancomycin</keyword>
  <keyword>gentamicin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan to make individual participant data available to other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

